Citizens Jmp Expects Weaker Earnings for National Research

National Research Corporation (NASDAQ:NRC) – Equities researchers at Citizens Jmp lowered their FY2026 EPS estimates for National Research in a report issued on Thursday, October 29th. Citizens Jmp analyst C. Davides now anticipates that the company will post earnings per share of $0.97 for the year, down from their prior estimate of $0.98. Citizens Jmp has a “Market Outperform” rating and a $27.00 price target on the stock. The consensus estimate for National Research’s current full-year earnings is $0.97 per share. Citizens Jmp also issued estimates for National Research’s Q4 2026 earnings at $0.24 EPS, Q1 2027 earnings at $0.23 EPS and FY2027 earnings at $1.06 EPS.

National Research (NASDAQ:NRC) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.03. National Research had a return on equity of 171.97% and a net margin of 4.48%. The company had revenue of $38.40 million for the quarter, compared to analyst estimates of $35.80 million.

Several other research firms also recently weighed in on NRC. Weiss Ratings upgraded National Research from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Zacks Research upgraded National Research to a “hold” rating in a report on Monday, October 5th. Finally, Wall Street Zen cut National Research from a “buy” rating to a “hold” rating in a report on Saturday, August 15th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, National Research currently has an average rating of “Hold” and an average target price of $27.00.

National Research Price Performance

Shares of NASDAQ:NRC opened at $24.07 on Monday. The company has a market cap of $547.59 million, a P/E ratio of 85.97 and a beta of 0.22. The company has a quick ratio of 0.65, a current ratio of 0.65 and a debt-to-equity ratio of 13.13. National Research has a 52 week low of $11.73 and a 52 week high of $24.69. The business has a fifty day simple moving average of $21.30 and a 200-day simple moving average of $19.24.

Institutional Trading of National Research

A number of institutional investors and hedge funds have recently made changes to their positions in NRC. Farmers & Merchants Investments Inc. increased its stake in National Research by 51.7% during the third quarter. Farmers & Merchants Investments Inc. now owns 501,731 shares of the company’s stock worth $10,632,000 after acquiring an additional 171,082 shares during the last quarter. Heartland Advisors Inc. raised its holdings in shares of National Research by 374.3% in the 1st quarter. Heartland Advisors Inc. now owns 237,147 shares of the company’s stock worth $4,027,000 after purchasing an additional 187,147 shares during the period. Fifth Third Bancorp acquired a new position in shares of National Research in the 1st quarter valued at about $1,531,000. Quantinno Capital Management LP lifted its stake in shares of National Research by 61.3% in the 1st quarter. Quantinno Capital Management LP now owns 62,329 shares of the company’s stock valued at $1,058,000 after purchasing an additional 23,682 shares in the last quarter. Finally, Integrity Alliance LLC. purchased a new stake in shares of National Research during the 3rd quarter worth about $538,000. 47.26% of the stock is currently owned by institutional investors and hedge funds.

National Research Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 8th. Stockholders of record on Tuesday, December 29th will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Tuesday, December 29th. This represents a $0.64 annualized dividend and a dividend yield of 2.7%. National Research’s payout ratio is currently 228.57%.

National Research Company Profile

National Research Corporation, formerly traded on the Nasdaq under the symbol NRC, provides research, analytics and performance-improvement services to the health care industry. Through its NRC Health business, the company helps hospitals, health systems and other care organizations understand and improve patient, consumer and employee experiences.

Its offerings have included patient and employee surveys, market research, reputation management, loyalty and engagement programs, benchmarking, and software tools that turn feedback and other data into operational insights.